HIMS (HIMS)

{"actual_eps":"0.08","est_eps":"0.04","actual_rev":"$617.8M","est_rev":"$619M","guidance_summary":"Management provided full-year 2026 revenue guidance in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million, signaling continued investment in international expansion and new specialties. However, Q1 2026 revenue guidance of $600 million to $625 million was below analyst estimates, and Q1 2026 Adjusted EBITDA margin is guided to compress to 6-9%, a sharp reversal from previous periods.","ai_interpretation":"MIXED SIGNAL. Hims & Hers delivered an EPS beat, but revenue was slightly below expectations. While full-year 2026 guidance implies continued growth, near-term Q1 2026 guidance signals a significant top-line deceleration and margin compression, driven by heavy investments in international expansion and new specialty launches. Regulatory scrutiny on GLP-1 products and negative free cash flow are also concerns.","verdict":"HOLD","executive_summary":"Hims & Hers reported Q4 2025 adjusted EPS of $0.08, beating the consensus estimate of $0.04. Revenue of $617.8 million slightly missed the $619 million consensus. The company provided full-year 2026 revenue guidance of $2.7 billion to $2.9 billion. However, Q1 2026 guidance indicated a significant deceleration in revenue growth and anticipated margin compression due to strategic investments and ongoing regulatory scrutiny.","investment_score":{"total":65}}